LPCN

Lipocine Inc. (LPCN) | Rumor.io

Lipocine

LPCN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,154

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.19

Market capitalization17.2M

Earnings per share-1.85

Dividend yield (TTM)—

Revenue (annual)2M

Net income (annual)-9.6M

Social

What share of all stock conversation is about LPCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jun 17

Lipocine Inc. (LPCN) has been mentioned in multiple posts, but none of the posts provide any market-relevant information about the company.
There is no market-relevant information available for Lipocine Inc. (LPCN) in the provided social media posts.
No specific news or updates about Lipocine Inc. (LPCN) are mentioned in the social media posts.

Generated by AI

Sentiment

Of the messages about LPCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.25% +0.37
Bearish	—	—	0% 0	7.75% -0.37

Bullish· Apr 10

$LPCN is forming a bottom pattern, with a potential squeeze zone around $2.25, which could lead to a significant price increase.
Insiders are buying a large number of shares in $LPCN, suggesting that they have confidence in the company's future prospects and are likely to benefit from any price increase.
$LPCN has shown strong volume on recent trading days, including a breakout over $2.25, which could be a sign of a larger price movement.

Bearish· Apr 2

The company's FDA-approved testosterone product is not selling well, which may indicate a lack of demand for the company's products.
The company's low float could lead to a sharp price increase, potentially causing a short squeeze, but this is not a guarantee of a positive outcome.
The company's financial situation is precarious, with the potential need to raise more money, which may lead to further declines in the stock price.

Generated by AI

Topics

Of the messages about LPCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	26.84%
Analysts	—	—	0%	31.97%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.26%
Macro	—	—	0%	28.29%
Technical Analysis	—	—	0%	12.63%

Earnings· Nov 8

$LPCN reported a loss of $0.22, beating consensus of ($0.27).
The company's earnings per share (EPS) beat expectations.
This result may be viewed as a positive for investors.

Announcements· Apr 2

Lipocine Inc. reported topline safety and efficacy results for LPCN 1154 in patients with postpartum depression, indicating positive findings in their clinical study.
Lipocine's stock price has fallen following the failure of its drug, LPCN 1154, to meet the primary endpoint in a Phase 3 trial for postpartum depression.
Lipocine Inc. has updated its corporate presentation used for investor meetings, which included plans to preserve capital and engage with stakeholders to evaluate options for the company's future, including continued development of LPCN 1154.

Controversies· May 26

Lipocine Inc. (LPCN) lost a patent infringement lawsuit against Clarus Therapeutics on summary judgment, with the court finding three of Lipocine's patents invalid.
The outcome of the lawsuit does not affect Lipocine's long-term plans, including the launch of TLANDO in 2022, and the company has not suffered any damages or penalties.
The remaining issue of "inequitable conduct" between the two companies will be tried before a judge, with its disposition expected to be addressed at a future date.

Technical Analysis· Jan 10

$LPCN is showing a gap fill possibility to $0.66.
The chart has an ascending triangle setting up, with a possible next leg up over $0.48.
The stock is looking healthy, with a target of $0.52 and potentially $0.66+ beyond.

Generated by AI

Community

Of the messages about LPCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	86.79%	46.02%
Newcomers	0%	0%	13.21%	53.98%

Regulars· Apr 2

Lipocine Inc.'s LPCN 1154 did not meet the endpoint in its Phase 3 trial for treating postpartum depression.
The company reported topline safety and efficacy results for LPCN 1154, indicating positive findings in its clinical study.
Lipocine Inc. updated its corporate presentation used for investor meetings, reported on April 2, 2026.

Newcomers· Apr 3

The CEO of LPCN made a significant insider buy, signaling confidence in the company's future.
The stock price of LPCN plummeted by 77.84% after a postpartum depression study failure, crushing the stock.
The FDA issued a CRL (Complete Response Letter) rejecting TLANDO XR, a major setback for LPCN.

Generated by AI

News

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

6d agoYahoo Finance

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.

20d agoYahoo Finance

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

1mo agoYahoo Finance

Also Discussed

Investors talking about LPCN also mention

#	Name	Attention
1	TRVN - Trevena, Inc.	——
2	Eton Pharmaceuticals, Inc.ETON	0%-0.01
3	AGRX - Agile Therapeutics, Inc.	——
4	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
5	Fennec Pharmaceuticals Inc.FENC	0%0
6	DRRX - DURECT Corporation	——
7	ALRN - Aileron Therapeutics, Inc.	——
8	EVOK - Evoke Pharma, Inc.	——
9	TCON - TRACON Pharmaceuticals, Inc.	——
10	MRNS - Marinus Pharmaceuticals, Inc.	——

Lipocine Inc.

Healthcare
Biotechnology

Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate. The company’s current portfolio includes TLANDO, an oral testosterone replacement therapy for men with low testosterone, and LPCN 1154 (BRLIZIO™), an oral neurosteroid under development for postpartum depression. Lipocine also advances additional product candidates across hormone-related, liver, and women’s health areas, using its proprietary delivery technology platform to support convenient oral dosing and differentiated therapeutic profiles. Based in Salt Lake City, Utah, Lipocine operates in the specialty pharmaceuticals and clinical-stage biotechnology markets, with its work centered on translating complex drug molecules into patient-friendly oral treatments.

Website

Location

675 Arapeen Drive

Salt Lake City, UT, 84108

United States

Social

What share of all stock conversation is about LPCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jun 17

Lipocine Inc. (LPCN) has been mentioned in multiple posts, but none of the posts provide any market-relevant information about the company.
There is no market-relevant information available for Lipocine Inc. (LPCN) in the provided social media posts.
No specific news or updates about Lipocine Inc. (LPCN) are mentioned in the social media posts.

Generated by AI

Sentiment

Of the messages about LPCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.25% +0.37
Bearish	—	—	0% 0	7.75% -0.37

Bullish· Apr 10

$LPCN is forming a bottom pattern, with a potential squeeze zone around $2.25, which could lead to a significant price increase.
Insiders are buying a large number of shares in $LPCN, suggesting that they have confidence in the company's future prospects and are likely to benefit from any price increase.
$LPCN has shown strong volume on recent trading days, including a breakout over $2.25, which could be a sign of a larger price movement.

Bearish· Apr 2

The company's FDA-approved testosterone product is not selling well, which may indicate a lack of demand for the company's products.
The company's low float could lead to a sharp price increase, potentially causing a short squeeze, but this is not a guarantee of a positive outcome.
The company's financial situation is precarious, with the potential need to raise more money, which may lead to further declines in the stock price.

Generated by AI

Topics

Of the messages about LPCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	26.84%
Analysts	—	—	0%	31.97%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.26%
Macro	—	—	0%	28.29%
Technical Analysis	—	—	0%	12.63%

Earnings· Nov 8

$LPCN reported a loss of $0.22, beating consensus of ($0.27).
The company's earnings per share (EPS) beat expectations.
This result may be viewed as a positive for investors.

Announcements· Apr 2

Lipocine Inc. reported topline safety and efficacy results for LPCN 1154 in patients with postpartum depression, indicating positive findings in their clinical study.
Lipocine's stock price has fallen following the failure of its drug, LPCN 1154, to meet the primary endpoint in a Phase 3 trial for postpartum depression.
Lipocine Inc. has updated its corporate presentation used for investor meetings, which included plans to preserve capital and engage with stakeholders to evaluate options for the company's future, including continued development of LPCN 1154.

Controversies· May 26

Lipocine Inc. (LPCN) lost a patent infringement lawsuit against Clarus Therapeutics on summary judgment, with the court finding three of Lipocine's patents invalid.
The outcome of the lawsuit does not affect Lipocine's long-term plans, including the launch of TLANDO in 2022, and the company has not suffered any damages or penalties.
The remaining issue of "inequitable conduct" between the two companies will be tried before a judge, with its disposition expected to be addressed at a future date.

Technical Analysis· Jan 10

$LPCN is showing a gap fill possibility to $0.66.
The chart has an ascending triangle setting up, with a possible next leg up over $0.48.
The stock is looking healthy, with a target of $0.52 and potentially $0.66+ beyond.

Generated by AI

Community

Of the messages about LPCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	86.79%	46.02%
Newcomers	0%	0%	13.21%	53.98%

Regulars· Apr 2

Lipocine Inc.'s LPCN 1154 did not meet the endpoint in its Phase 3 trial for treating postpartum depression.
The company reported topline safety and efficacy results for LPCN 1154, indicating positive findings in its clinical study.
Lipocine Inc. updated its corporate presentation used for investor meetings, reported on April 2, 2026.

Newcomers· Apr 3

The CEO of LPCN made a significant insider buy, signaling confidence in the company's future.
The stock price of LPCN plummeted by 77.84% after a postpartum depression study failure, crushing the stock.
The FDA issued a CRL (Complete Response Letter) rejecting TLANDO XR, a major setback for LPCN.

Generated by AI

Lipocine

Social

Jun 17

Bullish· Apr 10

Bearish· Apr 2

Earnings· Nov 8

Announcements· Apr 2

Controversies· May 26

Technical Analysis· Jan 10

Regulars· Apr 2

Newcomers· Apr 3

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

Lipocine stock price target maintained at $4 by H.C. Wainwright

Lipocine initiates phase 3 trial for postpartum depression drug

Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

Also Discussed

Lipocine Inc.

Company Information

Location

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

Lipocine stock price target maintained at $4 by H.C. Wainwright

Lipocine initiates phase 3 trial for postpartum depression drug

Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

Also Discussed

Social

Jun 17

Bullish· Apr 10

Bearish· Apr 2

Earnings· Nov 8

Announcements· Apr 2

Controversies· May 26

Technical Analysis· Jan 10

Regulars· Apr 2

Newcomers· Apr 3